Viking Therapeutics Inc. (VKTX) on Thursday announced that it has completed enrollment in the Phase 3 trial of its obesity drug, VK2735, which is in the race to compete in the GLP-1 obesity drug market, dominated by Novo Nordisk's Ozempic and Wegovy.
The company said that the Phase 3 VANQUISH-2 study will assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.
Viking is developing VK2735 in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.
Viking Therapeutics shares were down 1% in Thursday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory.
Get updates to this story developing directly on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.